Faculty Profiles - MIZUNO, Masashi

Papers - MIZUNO, Masashi

Division display 281 - 300 of about 350 ／ All the affair displays >>

Non-dipping is a potent predictor of cardiovascular mortality and is associated with autonomic dysfunction in haemodialysis patients Reviewed International journal Open Access

Liu MC, Takahashi H, Morita Y, Maruyama S, Mizuno M, Yuzawa Y, Watanabe M, Toriyama T, Kawahara H, Matsuo S

NEPHROLOGY DIALYSIS TRANSPLANTATION Vol. 18 ( 3 ) page： 563 - 569 2003.3

Non-dipping is a potent predictor of cardiovascular mortality and is associated with autonomic dysfunction in haemodialysis patients. Reviewed

Liu M., Takahashi H., Morita Y., Maruyama S., Mizuno M., Yuzawa Y., Watanabe M., Toriyama T., Kawahara H., MatsuoS.

Nephrol Dial Transplant. Vol. 18 page： 563-569 2003

Implication of the complement system in the induction of anti-glomerular basement membrane glomerulonephritis in WKY rats. Pathol. Reviewed

Shike T., Isome M., Mizuno M., Suzuki J., Matsuo S., Yamamoto T., Suzuki H.

Pathol. Int. Vol. 53 page： 757-761 2003

The nephrotoxicity of Aristolochia manshuriensis in rats is attributable to its aristolochic acids. Reviewed

Liu MC., Maruyama S., Mizuno M., Morita Y., Hanaki S., Yuzawa Y., Matsuo, S.

Clin Exp Nephrol Vol. 7 page： 186-194 2003

Characterization of the mouse analogues of CD59 using novel monoclonal antibodies: tissue distribution and functional comparison. Reviewed

Harris CL., Hanna SM., Mizuno M., Holt DS., Marchbank KJ., Morgan BP.

Immunology Vol. 109 page： 117-126 2003

Nephrogenic diabetes insipidus associated with hemochromatosis Reviewed International journal

Okumura A, Kondo K, Hirai C, Nishimura H, Tamai H, Kawarazaki F, Ichikawa M, Mizuno M, Oiso Y, Yamamoto M

AMERICAN JOURNAL OF KIDNEY DISEASES Vol. 40 ( 2 ) page： 403 - 406 2002.8

P-selectin-dependent macrophage migration into the tubulointerstitium in unilateral ureteral obstruction Reviewed International journal Open Access

Naruse T, Yuzawa Y, Akahori T, Mizuno M, Maruyama S, Kannagi R, Hotta N, Matsuo S

KIDNEY INTERNATIONAL Vol. 62 ( 1 ) page： 94 - 105 2002.7

The use of polysulfone hemodialysis membrane may improve hyperlipemia in patients receiving long-term maintenance hemodialysis Reviewed

MIZUNO Masashi, KOBAYASHI Kaoru, NAKATA Atsuhiro, WATANABE Midoriko, TORIYAMA Takanobu, KAWAHARA Hirohisa, MATSUO Seiichi

Vol. 35 ( 1 ) page： 43 - 49 2002.1

Soluble complement receptor type 1 protects rats from lethal shock induced by anti-Crry antibody following lipopolysaccharide priming

Mizuno M, Nishikawa K, Okada N, Matsuo S, Okada H

INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY Vol. 127 ( 1 ) page： 55 - 62 2002.1

Soluble complement receptor type 1 protects rats from lethal shock induced by anti-Crry antibody following lipopolysaccharide priming.

Mizuno M, Nishikawa K, Okada N, Matsuo S, Okada H

International archives of allergy and immunology Vol. 127 ( 1 ) page： 55 - 62 2002.1

二次性副甲状腺機能亢進症に対するmaxacalcitorol（オキサロールＲ）静注パルス療法の効果 ―早期低用量使用の試みー Reviewed Open Access

渡辺緑子、中田敦博、八島影人、河出恭雅、佐藤悌、小杉智規、鳥山高伸、河原弘久、水野正司、森田良樹、松尾清一

日本透析医学会誌 Vol. 35 page： 1193-1250 2002

高脂血症を伴う長期維持血液透析患者におけるポリスルフォン膜(PS-UW)の有用性について Reviewed

水野正司、小林薫、中田淳博、渡辺緑子、鳥山高伸、川原弘久、松尾清一

日本透析医学会雑誌 Vol. 35 page： 43-49 2002

Soluble CR1 protects rats from lethal shock induced by anti-Crry antibody following LPS priming. Reviewed

Mizuno M., Nishikawa K., Okada N., Mastuo S., Okada H.

Internal. Arch. Allergy Immunol. Vol. 127 page： 55-62 2002

Nephrogenic diabetes insipidus associated with hemochromatosis. Reviewed

Okumura A., Kondo K., Hirai C., Nishimura H., Tamai H., Kawarazaki F., Ichikaraki M., Mizuno M., Oiso Y., Yamamoto M.

Am J Kidney Dis Vol. 40 page： 403-406 2002

P-selectin-dependent macrophage migration into the tubulointerstitium in unilateral ureteral obstruction. Reviewed

Naruse T., Yuzawa Y., Akahori T, Mizuno M., Maruyama S., Kannagi R., Hotta S., Matsuo S.

Kidney Int. Vol. 62 page： 94-105 2002

The effects of low-dose intravenous maxacalcitol therapy on mild secondary hyperparathyroidism. Reviewed

Watanabe Midoriko, Nakata Atsuhiro, Yashima Akihito, Kawade Yasumasa, Sato Yasushi, Kosugi Tomoki, Toriyama Takanobu, Kawahara Hirohisa, Mizuno Masashi, Morita Yoshiki, Matsuo Seiichi

Nihon Toseki Igakkai Zasshi Vol. 35 ( 8 ) page： 1193 - 1198 2002

Language：Japanese Publishing type：Research paper (scientific journal) Publisher：The Japanese Society for Dialysis Therapy

This study evaluated the effects of low-dose i. v. maxacalcitol (OXAROL<sup>®</sup> OCT) in controlling mild secondary hyperparathyroidism (II° HPT) in chronic hemodialysis patients. Nineteen patients were selected for treatment because of increased parathyroid hormone (PTH) levels de spite administration of vitamin D (VD). The patients consisted of 15 males and 4 females, and were divided into 2 groups based on serum intact-PTH (i-PTH) levels (group I; N=11, 240pg/mL≤i-PTH<360pg/mL, group II; N=8, 360pg/mL≤i-PTH<500pg/mL). After a 2-week wash-out period for oral VD, OCT was given intravenously at a dose of 2.5μg in group I and 5.0μg in group II at the end of dialysis therapy 3 times/week. The dose was adjusted to maintain serum i-PTH levels at 240-500pg/mL and normal calcium (Ca) levels. During the 48-week observation period, serum i-PTH decreased significantly in both groups. Serum Ca levels increased mildly in both groups, but they remained within the normal range. Serum levels of phosphorus, ALP, bone ALP and osteocalcin were not significantly changed in either group. There was no correlation between parathyroid gland volume and i-PTH level. These findings suggest that long-term intravenous treatment with low-dose OCT is a useful strategy for the treatment of mild II° HPT without significant increase of serum Ca.

DOI： 10.4009/jsdt.35.1193

CiNii Research

The use of polysulfone hemodialysis membrane may improve hyperlipemia in patients receiving long-term maintenance hemodialysis. Reviewed

Mizuno Masashi, Kobayashi Kaoru, Nakata Atsuhiro, Toriyama Takanobu, Watanabe Midoriko, Matsuo Seiichi, Kawahara Hirohisa

Nihon Toseki Igakkai Zasshi Vol. 35 ( 1 ) page： 43 - 49 2002

Authorship：Lead author,　Corresponding author Language：Japanese Publishing type：Research paper (scientific journal) Publisher：The Japanese Society for Dialysis Therapy

Ischemic heart disease, cerebral hemorrhage, and cerebral embolus are severe complications seen in patients on maintenance hemodialysis. Hyperlipidemia is one of the risk factors profoundly associated with these complications. We investigated whether the use of polysulfone (PS) hemodialysis membrane improved serum levels of some lipid components in 6 non-DM patients on long-term maintenance hemodialysis. These 6 non-DM patients (one treated with CTA-membrane, 5 with EVAL-membrane) had hyperlipidemia (total cholesterol (TC) 263±17mg/dL, triglyceride (TG) 176±20mg/dL). Three patients were administered 5mg/day of Pravastatin sodium as an anti-hyperlipidemic drug, and one received 20mg/day of the same drug. We measured serum levels of TC, TG, LDL-C, HDL-C, LDL-TG, HDL-TG, Apo-A1, Apo-C3 and other factors before and 1 week after, then 1, 3, 5 and 6 months after the change in hemodialysis membrane. The serum TC level started to decrease after changing the membrane, and it decreased to 212±8mg/dL 3 months after that. Serum levels of LDL-C, Apo-A1 and Apo-C3 had significantly decreased at 6 months after the use of PS-membrane. However, serum levels of HDL-C and TG saw no change after the use of PS-membrane.<br>In addition, we tried to decrease or stop anti-hyperlipidemic drugs 6 months after the change in hemodialysis membrane when serum levels of TC had decreased and remained under 200mg/dL. One of the subjects did not need any drugs associated with hyperlipidemia. Another needed to have an anti-hyperlipidemic drug readministered about 4 months after the drug had been stopped.<br>In the present study, the PS-membrane might improve the hyperlipidemic profiles in patients on long-term hemodialysis. It was suggested that the use of PS-membrane might be available to decrease the dosage of antihyperlipidemia drugs or stop the administration of these drugs in hyperlipidemic patients on maintenance hemodialysis.

DOI： 10.4009/jsdt.35.43

CiNii Research

高脂血症を伴う長期維持血液透析患者におけるポリスルフォン膜(PS-UW)の有用性について Reviewed

水野正司, 小林薫, 中田淳博, 渡辺緑子, 鳥山高伸, 川原弘久, 松尾清一

日本透析医学会雑誌 Vol. 35 page： 43-49 2002

二次性副甲状腺機能亢進症に対するmaxacalcitorol（オキサロールＲ）静注パルス療法の効果 ―早期低用量使用の試みー Reviewed Open Access

渡辺緑子, 中田敦博, 八島影人, 河出恭雅, 佐藤悌, 小杉智規, 鳥山高伸, 河原弘久, 水野正司, 森田良樹, 松尾清一

日本透析医学会誌 Vol. 35 page： 1193-1250 2002

Blockage of complement regulators in the conjunctiva and within the eye leads to massive inflammation and iritis Reviewed

DS Bardenstein, CJ Cheyer, C Lee, E Cocuzzi, M Mizuno, N Okada, ME Medof

IMMUNOLOGY Vol. 104 ( 4 ) page： 423 - 430 2001.12

Language：English Publishing type：Research paper (scientific journal) Publisher：BLACKWELL SCIENCE LTD

The open environment of the eye is continuously subject to an influx of foreign agents that can activate complement. Decay-accelerating factor (DAF), membrane cofactor protein (MCP) and CD59 are regulators that protect self-cells from autologous complement activation on their surfaces. They are expressed in the eye at unusually high levels but their physiological importance in this site is unstudied. In the rat, a structural analogue termed 5I2 antigen (5I2 Ag) has actions overlapping DAF and MCP. In this investigation, we injected F(ab')(2) fragments of 5I2 mAb into the conjunctiva and aqueous humor, in the latter case with and without concomitant blockage of CD59. Massive neutrophilic infiltration of the stroma and iris resulted upon blocking 5I2 Ag activity. Frank necrosis of the iris occurred upon concomitant intraocular blockage of CD59. C3b was identified immunohistochemically, and minimal effects were seen in complement-depleted animals and in those treated with non-relevant antibody. The finding that block-age of 5I2 Ag function in periocular tissues and within the eye causes intense conjunctival inflammation and iritis demonstrates the importance of intrinsic complement regulators in protecting ocular tissues from spontaneous or bystander attack by autologous complement.

DOI： 10.1046/j.1365-2567.2001.01316.x

Web of Science

researchmap

　 PREV - NEXT 　

<MIZUNO, Masashi>

Papers - MIZUNO, Masashi